Form 4: Jazz Pharmaceuticals EVP Neena Patil Reports Stock Transactions
SEC Form 4 Filing
Neena Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals, reports the sale and acquisition of ordinary shares and restricted stock units.
Summary
- Neena Patil, the EVP & Chief Legal Officer of Jazz Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On February 27, 2025, Patil sold 3,800 ordinary shares at a weighted average price of $144.87.
- Patil also acquired 12,518 restricted stock units that vest in equal annual installments over four years starting March 5, 2025.
- Additionally, Patil acquired 5,778 restricted stock units that will vest in full on June 30, 2026.
- Following these transactions, Patil beneficially owns 51,614 ordinary shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock transactions.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry.
Stakeholder Impact
- Shareholders are informed about the stock transactions of a key executive.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of stock sale and acquisition of restricted stock units. |
| 03/03/2025 | Date of Form 4 filing. |
| 03/05/2025 | Vesting commencement date for 12,518 restricted stock units. |
| 06/30/2026 | Full vesting date for 5,778 restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.